fhjhiscock
02 Oct 2018
Major Shareholdings Thanks mol…nothing changes… Reneuron s downward slide and your well respected reported facts. Why an earth is the licensing of the manufacturing facility…the goldmine for almost immediate revenue stream, taking so long …I’ll bet a pound to a penny an agreement with a third party hinges on its award . I would also add that patience is the key but I’ve run out of steam…
mol42
01 Oct 2018
Major Shareholdings oops Woodford Investment Management LLP 35.39% Invesco Ltd 11.91% Wales Life Sciences Investment Fund LP 9.48% this following on from a matter of days between agm update and news re hRPC usa deal not proceeding suppose we did get $2.5m into coffers - anyway twill be spent on exec salaries and ever increasing unnecessary overhead admin and forgot to mention still providing options to non-execs - against recommendation of aim guidelines as i’ve noted on several occasions mol
mol42
01 Oct 2018
Major Shareholdings updated 280918 The current issued share capital of the Company, including shares issued under its blocklisting facility, is 31,646,186 ordinary shares. No shares are held as treasury. The Directors (together with their families and their family trusts and pension scheme arrangements) in aggregate hold 309,590 ordinary shares in the Company, representing 0.98% of the Company’s current issued share capital. 48.28% of the issued share capital is not in public hands. The Company is aware of the following significant (3% or greater) shareholdings in the Company’s ordinary shares: The above information was last updated on Friday, 28 September 2018 obviously updated due to derisory purchases by oh and mh on 27th and then followed by option grants on 28th! hard to make this up really mol
mol42
01 Oct 2018
Major Shareholdings Updated 280918
stutes
20 Sep 2018
New CEO Yes and why there should be a clear out immediately.
Prospero68
20 Sep 2018
New CEO As well as losing faith in the management team probably.
stutes
19 Sep 2018
New CEO The volume of shares show the fall is more down to City not wanting to sit on shares?
Prospero68
19 Sep 2018
New CEO Sick to death of the poor communications, missed deadlines, zero commercial acumen and poor investment decisions. The only reason I’m still in this dog is that I’ve lost over 90% of my investment and am too pigheaded to cut my losses and walk away. Where there is good news the SP drops immediately afterwards, when there is bad news it drops and stays down. When will we actually see some revenue coming in?
stutes
19 Sep 2018
New CEO The CEO has seen the share price fall, delays on trials, still to secure jvs for Rene. Overall where is the value added? Time for a new CEO and Regulatory person to deliver timely trials. We need people who will deliver the goods.
stutes
19 Sep 2018
Share price drops Well the talks on jv have ended - without a jv company may need cash to bankroll trials/ delays to stroke programme? I think it should put itself up for sale
stutes
18 Sep 2018
Stroke trial in USA S Golzari The fall in the share price should make Board start to think Rene needs a new CEO or to be part of a pharma that can drive trials to a commercial end. The record of delays and missed opportunity seems to follow Rene. Why should any management, who have seen a fall in value, be rewarded with share options at the devalued price - why not say £5 or more based on last share placement? Time to make management feel the heat.
s.golzari
16 Sep 2018
Stroke trial in USA I’m as impatient and frustrated as anyone and certainly understand the feelings of other long sugfering share holders with rene. However, I won’t second guess what is going on behind the scenes. Post stroke debilitation is a very complex neurological condition and claiming to be able to treat it will no doubt be a very charged and hyped affair. I would rather they take their time, do their due dilligence and get it right than botch it up in some rush to appease the market.
stutes
14 Sep 2018
Stroke trial in USA I wonder if Rene’s stroke trial holds the record for the longest delay in the pharma research? Time to sack a fe?
stutes
13 Sep 2018
Stroke trial in USA The company’s record on trials might stop shareholders backing any new capital raising unless there is a clear out of under performing management/staff.
charlton_vach
13 Sep 2018
Stroke trial in USA I make you right Stutes but then have Reneuron ever reacted to market demands? I guess sourcing relevant candidates would be a factor though.
